Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study. (nature.com)

Authors: Cheng M … Liu M Journal: Nature Communications Published: 2026-08-15 DOI: https://doi.org/10.1038/s41467-026-76502-7